Regulation of IMP3 by EGFR signaling and repression by ERβ: Implications for triple-negative breast cancer

Oncogene

Volumn 31, Issue 44, 2012, Pages 4689-4697

  Samanta, S ^a   Sharma, V M ^a   Khan, A ^b   Mercurio, A M ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

breast cancer; EGFR; ERb; IMP3

Indexed keywords

BINDING PROTEIN; CD164 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GELATINASE B; LIGAND; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; SOMATOMEDIN;

ARTICLE; CANCER CELL; CANCER INVASION; DISEASE COURSE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 84869091854     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.620     Document Type: Article

References (52)

1. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999; 19: 1262-1270. (Pubitemid 29046868)
2. Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Develop 1999; 88: 95-99. (Pubitemid 29467415)
3. Mueller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H et al. Cloning of a gene highly overexpressed in cancer coding for a novel KHdomain containing protein. Oncogene 1997; 14: 2729-2733. (Pubitemid 27283112)
4. Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006; 7: 556-564. (Pubitemid 43923666)
5. Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Modern Pathol 2007; 20: 242-247. (Pubitemid 46422179)
6. Lu D, Yang X, Jiang NY, Woda BA, Liu Q, Dresser K et al. IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am J Surg Pathol 2011; 35: 1638-1645.
7. Simon R, Bourne PA, Yang Q, Spaulding BO, di Sant'Agnese PA, Wang HL et al. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol 2007; 38: 1178-1183. (Pubitemid 47058168)
8. Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 2005; 29: 188-195. (Pubitemid 40170636)
9. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 2008; 32: 304-315. (Pubitemid 351172146)
10. Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol 2009; 40: 1528-1533.
11. Li S, Cha J, Kim J, Kim KY, Kim HJ, Nam W et al. Insulin-like growth factor II mRNAbinding protein 3: a novel prognostic biomarker for oral squamous cell carcinoma. Head Neck 2011; 33: 368-374.
12. Li D, Yan D, Tang H, Zhou C, Fan J, Li S et al. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol 2009; 16: 3499-3506.
13. Irvin Jr WJ, Carey LA. What is triple-negative breast cancer? Eur J Cancer 2008; 44: 2799-2805.
14. Marotti JD, Collins LC, Hu R, Tamimi RM. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Modern Pathol 2010; 23: 197-204.
15. Foley J, Nickerson NK, Nam S, Allen KT, Gilmore JL, Nephew KP et al. EGFR signaling in breast cancer: bad to the bone. Semin Cell Dev Biol 2010; 21: 951-960.
16. Guerini V, Sau D, Scaccianoce E, Rusmini P, Ciana P, Maggi A et al. The androgen derivative 5alpha-androstane-3beta,17beta-diol inhibits prostate cancer cell migration through activation of the estrogen receptor beta subtype. Cancer Res 2005; 65: 5445-5453. (Pubitemid 40827358)
17. Zhang XT, Kang LG, Ding L, Vranic S, Gatalica Z, Wang ZY. A positive feedback loop of ER-alpha36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 2011; 30: 770-780.
18. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003; 284: 31-53. (Pubitemid 36331965)
19. Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 2001; 29: 2905-2919. (Pubitemid 32685217)
20. Klein-Hitpass L, Schorpp M, Wagner U, Ryffel GU. An estrogen-responsive element derived from the 5' flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells. Cell 1986; 46: 1053-1061. (Pubitemid 17182729)
21. Hafner M, Landthaler M, Burger L, Khorshid M, Hausser J, Berninger P et al. Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP. Cell 2010; 141: 129-141.
22. Havens AM, Jung Y, Sun YX, Wang J, Shah RB, Buhring HJ et al. The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis. BMC Cancer 2006; 6: 195.
23. Ellenbroek SI, Collard JG. Rho GTPases: functions and association with cancer. Clin Exp Metastas 2007; 24: 657-672. (Pubitemid 50002983)
24. +/+ cells. J Biol Chem 1999; 274: 11022-11029.
25. Sicinski P, Donaher JL, Geng Y, Parker SB, Gardner H, Park MY et al. Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 1996; 384: 470-474. (Pubitemid 26414665)
26. Vikesaa J, Hansen TV, Jonson L, Borup R, Wewer UM, Christiansen J et al. RNAbinding IMPs promote cell adhesion and invadopodia formation. EMBO J 2006; 25: 1456-1468.
27. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Gene Dev 1999; 13: 35-48. (Pubitemid 29045114)
28. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002; 161: 1991-1996. (Pubitemid 35434844)
29. Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H. Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol 2008; 61: 553-560. (Pubitemid 351678206)
30. Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004; 64: 423-428. (Pubitemid 38114127)
31. Webb P, Valentine C, Nguyen P, Price Jr RH, Marimuthu A, West BL et al. ERbeta binds N-CoR in the presence of estrogens via an LXXLL-like motif in the N-CoR Cterminus. Nuclear Receptor 2003; 1: 4.
32. Pinton G, Thomas W, Bellini P, Manente AG, Favoni RE, Harvey BJ et al. Estrogen receptor beta exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib. PloS One 2010; 5: e14110.
33. Ryden L, Jirstrom K, Haglund M, Stal O, Ferno M. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. Breast Cancer Res Tr 2010; 120: 491-498.
34. Garcia Castro C, Ravina M, Castro V, Salido EC. Expression of epidermal growth factor receptor (proto-oncogene c-erbB-1) and estrogen receptor in human breast carcinoma. An immunocytochemical study of 70 cases. Arch Gynecol Obstet 1993; 252: 169-177. (Pubitemid 23131623)
35. Martinazzi M, Crivelli F, Zampatti C, Martinazzi S. Epidermal growth factor receptor immunohistochemistry in different histological types of infiltrating breast carcinoma. J Clin Pathol 1993; 46: 1009-1010.
36. Newby JC, A'Hern RP, Leek RD, Smith IE, Harris AL, Dowsett M. Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand-binding assay and clinical relevance in breast cancer. Brit J Cancer 1995; 71: 1237-1242.
37. Heldin CH, Westermark B. Growth factors: mechanism of action and relation to oncogenes. Cell 1984; 37: 9-20. (Pubitemid 14079832)
38. Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z et al. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxiainducible factor-1alpha in non-small cell lung cancer cells. Oncogene 2010; 29: 2616-2627.
39. Van Meter TE, Broaddus WC, Rooprai HK, Pilkington GJ, Fillmore HL. Induction of membrane-type-1 matrix metalloproteinase by epidermal growth factormediated signaling in gliomas. Neuro-Oncology 2004; 6: 188-199. (Pubitemid 39136502)
40. Li Z, Xu X, Bai L, Chen W, Lin Y. Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cells. J Biol Chem 2011; 286: 21164-21172.
41. Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr-Relat Cancer 2005; 12 (Suppl 1): S135-S144. (Pubitemid 41395421)
42. Suvasini R, Shruti B, Thota B, Shinde SV, Friedmann-Morvinski D, Nawaz Z et al. Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2. J Biol Chem 2011; 286: 25882-25890.
43. Liao B, Hu Y, Brewer G. RNA-binding protein insulin-like growth factor mRNAbinding protein 3 (IMP-3) promotes cell survival via insulin-like growth factor II signaling after ionizing radiation. J Biol Chem 2011; 286: 31145-31152.
44. Zeng ZS, Cohen AM, Guillem JG. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 1999; 20: 749-755. (Pubitemid 29191855)
45. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003; 63: 5224-5229. (Pubitemid 37139832)
46. Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T et al. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients. Brit J Cancer 2001; 84: 1488-1496. (Pubitemid 32579341)
47. Liao B, Hu Y, Herrick DJ, Brewer G. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 2005; 280: 18517-18524. (Pubitemid 41389102)
48. Ellis MJ, Jenkins S, Hanfelt J, Redington ME, Taylor M, Leek R et al. Insulin-like growth factors in human breast cancer. Breast Cancer Res Tr 1998; 52: 175-184. (Pubitemid 29056094)
49. Bourguignon LY, Wong G, Earle C, Krueger K, Spevak CC. Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem 2010; 285: 36721-36735.
50. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, Deuel TF. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 2005; 336: 1023-1027. (Pubitemid 41383424)
51. Shaw LM, Rabinovitz I, Wang HH, Toker A, Mercurio AM. Activation of phosphoinositide 3-OH kinase by the alpha6beta4 integrin promotes carcinoma invasion. Cell 1997; 91: 949-960. (Pubitemid 28027828)
52. Mak P, Leung YK, Tang WY, Harwood C, Ho SM. Apigenin suppresses cancer cell growth through ERbeta. Neoplasia 2006; 8: 896-904. (Pubitemid 44706239)